ArticleEuropean journal of public health2026
Recognition, treatment, and control of hypertension in the Danish population-based Lolland-Falster Health Study.
Article in European journal of public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In the Danish population-based Lolland-Falster Health Study (LOFUS), conducted in a socioeconomically disadvantaged area with marked regional health inequalities, we recently identified a hypertension prevalence of 45%. A more detailed understanding of recognition, control, and treatment of hypertension in this setting may help improve interventions to reduce hypertension-related cardiovascular disease. This was a cross-sectional study including participants with hypertension identified in LOFUS using data from clinical examinations and questionnaires. Recognition was assessed by a registered diagnosis or self-reported hypertension and factors associated with recognition status were analyzed. Cardiovascular risk stratification was applied to individuals with unrecognized hypertension to determine treatment indication. Blood pressure (BP) control and antihypertensive treatment patterns were evaluated among participants with recognized hypertension. Among 7329 participants with hypertension, 39% were unrecognized. Individuals with unrecognized hypertension were younger, had higher educational attainment and fewer comorbidities than those with recognized hypertension. Larger household size was associated with higher odds of unrecognition. Two-thirds of individuals with unrecognized hypertension were classified as having high 10-year cardiovascular risk and met criteria for antihypertensive treatment. Among participants with recognized hypertension, 51% had uncontrolled BP despite >50% receiving ≥2 antihypertensive agents. The group with uncontrolled BP had fewer comorbidities than those with controlled BP. In this rural cohort with a high prevalence of hypertension, a large proportion remained unrecognized despite elevated cardiovascular risk, and among individuals with recognized hypertension, treatment targets were often not achieved. These findings indicate a substantial unmet need for improved recognition and management of hypertension, with important implications for public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.